Recent Patents for the Treatment of Asthma.
BACKGROUND
Despite adequate adherence and completion of anti-asthmatic treatment, many patients remain poorly controlled or uncontrolled. Asthma management is based on the use of medication to reverse the bronchial obstruction and eliminate the airway inflammation. New drug development is expected in the future as a consequence of discoveries in the pathophysiology and mechanisms of asthma. Currently, a good and effective set of treatments is available for these diseases. However, the search for new treatment modalities to improve the currently available is especially important for those patients unresponsive to current therapy.


OBJECTIVE
In this review, we summarize new anti-cytokines therapies, anti-leucotrienes molecules, immunomodulatory and anti-inflammatory agents, researched for treatment of asthma.


METHODS
Database patents were used for searching new patents from 2015 and from the beginning of 2016 about treatment of asthma.


CONCLUSIONS
Pharmacogenomic point of view is now being considered by most major pharmaceutical companies as line of investigation without end in the nearest horizon. Pharmacogenomics has the potential to notably improve the safety and effectiveness of medications.
Allergy Unit, Hospital La Plana, Carretera Vila-Real-Burriana Km 0.5 Vila-Real (Castellon) 12540, Spain. elqutob@comv.es.
David
D
El-Qutob
Isabela
I
Raducan
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D055808:Drug Discovery; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D010330:Patents as Topic; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D051193:Toll-Like Receptors / Q000819:agonists / Q000276:immunology / Q000378:metabolism
D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D016207:Cytokines; D018836:Inflammation Mediators; D020024:Leukotriene Antagonists; D010726:Phosphodiesterase Inhibitors; D051193:Toll-Like Receptors